A drug concentration that affects cells in a dish may differ from what can safely reach a tumor. Exposure includes the amount of drug, how long it remains available and the setting in which it is measured.
A primary compilation of oncology drug pharmacokinetics showed why nonclinical studies need concentrations relevant to measured human exposures. A high-concentration experiment can help investigate a mechanism without establishing that the effect is achievable clinically. Plasma concentration, free drug, exposure duration and tumor delivery are separate quantities; a reported peak concentration is not a universal concentration to use in every assay. The comparison must fit the drug, measured species and experimental conditions.
Shares Growth-rate correction in drug-response assays, Drug response and drug sensitivity (IC50, AUC), Evidence from measurement to patient benefit.
Shares Context of use for a tumor model, Drug response and drug sensitivity (IC50, AUC).
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Drug target engagement, Evidence from measurement to patient benefit.
Shares Binding-site barrier in tumor delivery, Evidence from measurement to patient benefit.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/